SCHEMBL3133705

SCHEMBL3133705

CCN1C(=O)C(=Cc2ccc(C)o2)SC1=S

nearest known ligand 0.72

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 12/20 0.72
▸ ALDH1A1 P00352 12/20 0.72
▸ KMT2A Q03164 11/20 0.72
▸ MEN1 O00255 10/20 0.72
▸ RECQL P46063 5/20 0.72
▸ LMNA P02545 4/20 0.72
▸ ALOX12 P18054 3/20 0.72
▸ MCL1 Q07820 2/20 0.72
▸ KDM4E B2RXH2 6/20 0.64
▸ PKM P14618 4/20 0.64
▸ POLB P06746 4/20 0.64
▸ MAPK1 P28482 3/20 0.64
▸ TDP1 Q9NUW8 3/20 0.64
▸ NPSR1 Q6W5P4 3/20 0.64
▸ RAB9A P51151 2/20 0.64
▸ L3MBTL1 Q9Y468 2/20 0.64
▸ STAT3 P40763 1/20 0.61
▸ TNFRSF1A P19438 2/20 0.59
▸ HTT P42858 3/20 0.57
▸ HPGD P15428 2/20 0.57

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3133698 1.00 MAPT (0.72) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL3133695 1.00 MAPT (0.72) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8189877 0.86 KMT2A (0.67) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8189870 0.86 KMT2A (0.67) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8189873 0.86 KMT2A (0.67) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8190456 0.82 MAPT (0.66) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8190455 0.82 MAPT (0.66) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL8191326 0.82 MAPT (0.66) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL3131533 0.81 STAT3 (0.78) MAPTALDH1A1KMT2AMEN1RECQL
SCHEMBL3131544 0.81 STAT3 (0.78) MAPTALDH1A1KMT2AMEN1RECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2012-08-30 — — US disclosed
WO-2010044924-A1 NOVEL ANTIVIRAL AGENTS FOR ENVELOPED VIRUSES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2010-04-22 — — WO disclosed
WO-2000032598-A1 METHODS AND COMPOSITIONS FOR TREATING INFLAMMATORY DISEASES UTILIZING INHIBITORS OF TUMOR NECROSIS FACTOR ACTIVITY STRUCTURAL BIOINFORMATICS INC. (US) 2000-06-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120219613-A1 Novel Antiviral Agents for Enveloped Viruses MAVS, LAMP1, HAVCR2 MAPT 3126/4885ALDH1A1 1264/4885KMT2A 2561/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback